Develops solutions for organ, tissue, and cell preservation and perfusion in transplantation. Now — the numbers.
This is an established company with proven profits.
Average growth of 31% a year over the last 4 years. Every year shown ended in profit.
If every debt were paid off today, $17.3M would still be left in the vault — a solid cushion for hard times.
The market pays 354.9× for every dollar this company earns in a year — a price that already assumes things go well.
No analyst target is on record for this company.
The stock trades 47% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 31% a year on average.
There is $30.2M in the vault; even if every debt were paid off, $17.3M would remain.
The company’s market value is 355 times its annual profit. Even a small disappointment could hit the price hard.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.